Anti-herpes simplex virus I-form medicament composition and uses thereof

A technology of herpes simplex virus and composition, which is applied in the directions of drug combination, antiviral agent, medical preparation containing active ingredients, etc., can solve the problems such as no dammarane-type tetracyclic triterpenoids and the like.

Inactive Publication Date: 2008-12-17
KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In the prior art, no dammarane-type tetracyclic triterpenoids are used as active ingredients in the preparation and treatment of diseases caused b

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-herpes simplex virus I-form medicament composition and uses thereof
  • Anti-herpes simplex virus I-form medicament composition and uses thereof
  • Anti-herpes simplex virus I-form medicament composition and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Extraction, separation and structure identification of 3 active compounds:

[0029] 5kg of Panax notoginseng was purchased in Yunnan. After being crushed into granules, it was wrapped with double gauze and placed in a pressure cooker. The temperature was controlled at a high temperature of 120°C. After being steamed for 12 hours, cooked Panax notoginseng was obtained. The cooked Panax notoginseng was extracted with industrial ethanol under reflux (5L×4), and the solvent was recovered under reduced pressure and concentrated to obtain 778 g of total extract. The extract was dissolved in water, column chromatography was performed with D101 macroporous adsorption resin (90×8.5cm), and the effluent was first eluted with water until the Molish reaction was negative, and then eluted with industrial methanol to obtain 440 g of crude saponin.

[0030] The crude saponin was mixed with 500 g of silica gel (200-300 mesh), and subjected to silica gel (200-300 mesh) dry column chromatogr...

Embodiment 2

[0041] Toxicity test of ginsenoside Rd(1) on Vero cells:

[0042] After the Vero cells are trypsinized, add 100μL / well to a 96-well culture plate. When the cells grow into a monolayer, discard the growth medium. Add 100μL of sample-containing maintenance solution to each well. Set four replicate wells for each dilution. Set up a normal cell control group with 5% CO 2 Incubate in an incubator at 37°C, observe the changes of the cells every day, and calculate the maximum non-toxic concentration TC of the drug 0 .

[0043] Results The maximum non-toxic concentration of ginsenoside Rd on Vero cells TC 0 At 200μg / mL, there is no obvious toxic effect.

Embodiment 3

[0045] The pharmacodynamic experiment of ginsenoside Rd(1) against HSV-1 virus:

[0046] Vero cells were cultured to a single layer in a 96-well plate, the growth medium was discarded, the sample maintenance solution was diluted to seven concentrations (within the maximum non-toxic range of the sample), and 50 μL of the sample maintenance solution and the virus dilution solution were added to each well. Set 4 multiple holes for each concentration, and set up positive control group, virus control group and normal cell control group at the same time, set 5% CO 2 Incubate in an incubator at 37°C and observe the condition of cytopathic (CPE) every day. When the cytopathic effect of the virus control group reaches 75% and above and the normal cell control group is normal, observe and record the CPE of each well, use the MTT method to detect the inhibitory rate of the sample against the virus, and calculate the half inhibitory concentration of the sample against HSV-1 (IC 50 ).

[0047]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound as an active component and an application thereof to the pharmaceutical field. Panax notoginseng is separated to obtain three dammarane-type tetracyclic triterpene compounds as shown in the following structural formula, in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for herpes simplex virus type I and can be applied to the preparation of medicines for resisting herpes simplex virus type I and is used for treating herpetic keratitis, encephalitis, pneumonia, ulcerative stomatitis, blister and the like caused by herpes simplex virus type I.

Description

Technical field [0001] The present invention belongs to the field of pharmaceutical compositions. Specifically, it relates to a pharmaceutical composition with dammarane-type tetracyclic triterpenoids as active ingredients. Application in medicine for oral ulcers and blisters caused by viral infections. Background technique [0002] The herpes simplex virus is a DNA virus, belonging to the herpesvirus family a virus subfamily. From four months to several years after the occurrence, the number of people infected can reach 50-90% of the total population. It is the most vulnerable virus to invade humans, but only a part of the disease is clinically affected. According to the difference of antigenicity, it can be divided into type I and type II. Herpes simplex virus type I (HSV-1) mainly causes infections of the skin, mucous membranes (oral mucosa), cornea, and organs (brain) other than the genitals. The clinical manifestations are mainly herpes that accumulate locally on the mucous ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K31/575A61P31/12A61P1/02
Inventor 张颖君王一飞廖彭莹裴赢杨崇仁王东
Owner KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap